Chinese Healthcare Firms Poised to Continue Out-Licensing Deals in 2026 -- Market Talk

Dow Jones12-12

0442 GMT - China's healthcare sector is likely to see continued out-licensing activity in 2026, though the markets may become more rational about the sector, Deutsche Bank analyst Cyrus Ng says in a note. He notes that China, which accounts for 11%-13% of global R&D drug spending yet contributes roughly 40% of innovative drugs in clinical development, will remain a key source of high-potential, low-cost pharma assets for global drugmakers. Still, the timing, size, partners, and cooperation model of out-licensing deals remain highly unpredictable, Ng says, adding that markets will start to view them as positive surprises rather than probable events. He expects investors should refocus on company fundamentals next year as more companies reach profitability amid an improving funding environment and a supportive policy landscape.(jason.chau@wsj.com)

(END) Dow Jones Newswires

December 11, 2025 23:42 ET (04:42 GMT)

At the request of the copyright holder, you need to log in to view this content

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2590155522?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-12-12 12:42","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2590155522","market":"nz","top_or_hot":-1,"title":"Chinese Healthcare Firms Poised to Continue Out-Licensing Deals in 2026 -- Market Talk","media":"Dow Jones","content":"<font class=\"NormalMinus1\" face=\"Arial\">\n<p>\n     0442 GMT - China's healthcare sector is likely to see continued out-licensing activity in 2026, though the markets may become more rational about the sector, Deutsche Bank analyst Cyrus Ng says in a note. He notes that China, which accounts for 11%-13% of global R&amp;D drug spending yet contributes roughly 40% of innovative drugs in clinical development, will remain a key source of high-potential, low-cost pharma assets for global drugmakers. Still, the timing, size, partners, and cooperation model of out-licensing deals remain highly unpredictable, Ng says, adding that markets will start to view them as positive surprises rather than probable events. He expects investors should refocus on company fundamentals next year as more companies reach profitability amid an improving funding environment and a supportive policy landscape.(jason.chau@wsj.com) \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  December 11, 2025 23:42 ET (04:42 GMT)\n</p>\n<p>\n  Copyright (c) 2025 Dow Jones &amp; Company, Inc.\n</p>\n</font>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Chinese Healthcare Firms Poised to Continue Out-Licensing Deals in 2026 -- Market Talk</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nChinese Healthcare Firms Poised to Continue Out-Licensing Deals in 2026 -- Market Talk\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Dow Jones </p>\n<p class=\"h-time\">2025-12-12 12:42</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<font class=\"NormalMinus1\" face=\"Arial\">\n<p>\n     0442 GMT - China's healthcare sector is likely to see continued out-licensing activity in 2026, though the markets may become more rational about the sector, Deutsche Bank analyst Cyrus Ng says in a note. He notes that China, which accounts for 11%-13% of global R&amp;D drug spending yet contributes roughly 40% of innovative drugs in clinical development, will remain a key source of high-potential, low-cost pharma assets for global drugmakers. Still, the timing, size, partners, and cooperation model of out-licensing deals remain highly unpredictable, Ng says, adding that markets will start to view them as positive surprises rather than probable events. He expects investors should refocus on company fundamentals next year as more companies reach profitability amid an improving funding environment and a supportive policy landscape.(jason.chau@wsj.com) \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  December 11, 2025 23:42 ET (04:42 GMT)\n</p>\n<p>\n  Copyright (c) 2025 Dow Jones &amp; Company, Inc.\n</p>\n</font>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"XLV","symbol_name":"健康照护类股ETF-SPDR","start_time":0,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","article_id":"2590155522","we_media_id":"106","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2590155522","pubTimestamp":1765514520,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Dow Jones","introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"summary":"0442 GMT - China's healthcare sector is likely to see continued out-licensing activity in 2026, though the markets may become more rational about the sector, Deutsche Bank analyst Cyrus Ng says in a note. He notes that China, which accounts for 11%-13% of global R&D drug spending yet contributes roughly 40% of innovative drugs in clinical development, will remain a key source of high-potential, low-cost pharma assets for global drugmakers. Still, the timing, size, partners, and cooperation model of out-licensing deals remain highly unpredictable, Ng says, adding that markets will start to view them as positive surprises rather than probable events. He expects investors should refocus on company fundamentals next year as more companies reach profitability amid an improving funding environment and a supportive policy landscape.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"XLV":"健康照护类股ETF-SPDR","XBI":"SPDR S&P Biotech ETF","BK4581":"高盛持仓","BK4585":"ETF&股票定投概念","LU0029874061.USD":"TEMPLETON GLOBAL SMALLER COMPANIES \"A\" YDIS INC","HCSG":"Healthcare Svcs Group Inc","BK4137":"综合支持服务","LU0128526141.USD":"TEMPLETON GLOBAL SMALLER COMPANIES \"A\" ACC","BK4588":"碎股","LABU":"三倍做多标普生物-Direxion"},"translate_title":"中国医疗保健公司准备在2026年继续进行授权交易——市场讨论","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"XLV":1.5,"LABU":0.6,"HCSG":1.5,"XBI":0.6},"content_text":"0442 GMT - China's healthcare sector is likely to see continued out-licensing activity in 2026, though the markets may become more rational about the sector, Deutsche Bank analyst Cyrus Ng says in a note. He notes that China, which accounts for 11%-13% of global R&D drug spending yet contributes roughly 40% of innovative drugs in clinical development, will remain a key source of high-potential, low-cost pharma assets for global drugmakers. Still, the timing, size, partners, and cooperation model of out-licensing deals remain highly unpredictable, Ng says, adding that markets will start to view them as positive surprises rather than probable events. He expects investors should refocus on company fundamentals next year as more companies reach profitability amid an improving funding environment and a supportive policy landscape.(jason.chau@wsj.com) \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  December 11, 2025 23:42 ET (04:42 GMT)\n\n\n  Copyright (c) 2025 Dow Jones & Company, Inc.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":true,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.12","shortVersion":"4.35.12","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2590155522","isCrawlerRequest":true}